Bristol-Myers Squibb to Announce Financial Results for Third Quarter 2011 on October 27

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE:BMY) will announce financial results for the third quarter of 2011 on Thursday, October 27, 2011. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com or by dialing 913-312-6687, confirmation code: 4909111. Materials related to the call will be available at the same website prior to the conference call. A replay of the call will be available beginning at 2:00 p.m. EDT on October 27 through midnight EDT on November 10, 2011. The replay will also be available through http://investor.bms.com or by dialing 402-280-9013, confirmation code: 4909111.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Practice Management  Health  Biotechnology  Infectious Diseases  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.